European Urology Oncology

Slides:

Advertisements

Similar presentations

Volume 68, Issue 6, Pages (December 2015)

Advertisements

Volume 66, Issue 2, Pages (August 2014)

Bone Scan Index as an Imaging Biomarker in Metastatic Castration-resistant Prostate Cancer: A Multicentre Study Based on Patients Treated with Abiraterone.

Oncol Res Treat 2016;39: DOI: /

Volume 69, Issue 5, Pages (May 2016)

Volume 68, Issue 4, Pages (October 2015)

Volume 66, Issue 5, Pages (November 2014)

European Urology Oncology

Volume 69, Issue 5, Pages (May 2016)

European Urology Oncology

Yair Lotan, Peter C. Black, Laura Caba, Sam S. Chang, Michael S

Volume 52, Issue 4, Pages (October 2007)

European Urology Oncology

Volume 68, Issue 4, Pages (October 2015)

Volume 65, Issue 5, Pages (May 2014)

Volume 74, Issue 1, Pages (July 2018)

Volume 65, Issue 3, Pages (March 2014)

Elizabeth K. Bancroft, Rosalind A. Eeles

Volume 65, Issue 1, Pages (January 2014)

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

European Urology Oncology

Volume 66, Issue 5, Pages (November 2014)

Volume 70, Issue 5, Pages (November 2016)

Laurent Boccon-Gibod European Urology Supplements

Active Surveillance for Prostate Cancer in a Real-life Cohort: Comparing Outcomes for PRIAS-eligible and PRIAS-ineligible Patients Timo F.W. Soeterik,

Volume 53, Issue 2, Pages (February 2008)

Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases Axel Heidenreich, Nicola Fossati, David Pfister, Nazareno Suardi,

Docetaxel Treatment in PTEN- and ERG-aberrant Metastatic Prostate Cancers Pasquale Rescigno, David Lorente, David Dolling, Roberta Ferraldeschi, Daniel.

Volume 66, Issue 6, Pages (December 2014)

Volume 72, Issue 1, Pages (July 2017)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 2, Pages (August 2018)

Is It Necessary to Detect All Prostate Cancers in Men with Serum PSA Levels

Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic.

Selma Masic, Janet E. Cowan, Samuel L. Washington, Hao G

Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base Amy C. Moreno,

European Urology Oncology

Impact of (A): metastatic sites (bone metastasis±lymph node metastasis vs visceral metastasis), (B): PSA response, (C): AA drug exposure duration on overall.

Volume 55, Issue 6, Pages (June 2009)

European Urology Oncology

Heterogeneity in Definitions of High-risk Prostate Cancer and Varying Impact on Mortality Rates after Radical Prostatectomy Matthew Mossanen, Kenneth.

Intermittent Hormone Therapy: What Is Its Place in Clinical Practice?

Optimizing the Timing of Salvage Postprostatectomy Radiotherapy and the Use of Concurrent Hormonal Therapy for Prostate Cancer Amar U. Kishan, Rahul.

Long-Term Hormonal Therapy: Who Would Benefit?

Volume 74, Issue 3, Pages (September 2018)

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Volume 59, Issue 4, Pages (April 2011)

Volume 71, Issue 4, Pages (April 2017)

Gender differences in treatment outcomes of tuberculosis patients in Taiwan: a prospective observational study J.-Y. Feng, S.-F. Huang, W.-Y. Ting, Y.-C.

European Urology Oncology

European Urology Oncology

Axel Heidenreich European Urology Supplements

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

European Urology Oncology

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

European Urology Oncology

Highlighting Unmet Needs: Real Patients, Difficult Choices

European Urology Oncology

European Urology Oncology

Oncoforum Urology: Prostate Cancer 2008 at a Glance

An elevated neutrophil-lymphocyte ratio independently predicts mortality in chronic critical limb ischemia James Ian Spark, MBChB, FRCS, MD, FRACS, Janahan.

Axel Heidenreich European Urology Supplements

European Urology Oncology

European Urology Oncology

European Urology Oncology

Kaplan-Meier curves for overall survival in patients with adenocarcinoma and time since first-line therapy of

European Urology Oncology

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

European Urology Oncology

Volume 69, Issue 4, Pages (April 2016)

Presentation transcript:

European Urology Oncology Neutrophil-to-lymphocyte Ratio as a Predictive Marker of Response to Abiraterone Acetate: A Retrospective Analysis of the COU302 Study Thomas Loubersac, Molière Nguile-Makao, Frédéric Pouliot, Vincent Fradet, Paul Toren European Urology Oncology DOI: 10.1016/j.euo.2019.01.009 Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 1 CONSORT diagram of patients included in the analysis. European Urology Oncology DOI: (10.1016/j.euo.2019.01.009) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 2 Neutrophil:lymphocyte ratio at screening, at the beginning of cycle 2, and at the end of the study by treatment arm. No significant differences between treatment arms were observed, but significant differences (***p<0.001) were observed between indicated time points. AA=abiraterone acetate. European Urology Oncology DOI: (10.1016/j.euo.2019.01.009) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 3 Neutrophil:lymphocyte ratio (NLR) as a predictive biomarker of response to abiraterone therapy. Kaplan-Meier survival curves showing differential responses to abiraterone acetate plus prednisone but not to placebo plus prednisone when stratified by baseline neutrophil:lymphocyte ratio. (A) Overall survival. (B) Time to radiographic progression. (C) Time to PSA progression. AA=abiraterone acetate; PSA=prostate-specific antigen. European Urology Oncology DOI: (10.1016/j.euo.2019.01.009) Copyright © 2019 European Association of Urology Terms and Conditions

Fig. 4 Effect of changes in neutrophil:lymphocyte ratio (NLR) on subsequent benefit of abiraterone acetate. Survival was calculated from the first absolute change of NLR from baseline under prednisone treatment on the 1st day of cycle 2 in the COU302 trial. Only patients with indicated changes are included in survival analysis. AA=abiraterone acetate; PSA=prostate-specific antigen. European Urology Oncology DOI: (10.1016/j.euo.2019.01.009) Copyright © 2019 European Association of Urology Terms and Conditions